Revenue
No reported data
CITIUS ONCOLOGY, INC. (CTOR)
Price—Loading quote
Net income
2021
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Research & development | $6.4M | $4.9M | — | — | — |
| Operating expenses | $23.5M | $20.6M | — | — | — |
| Operating income | −$23.5M | −$20.6M | −$1.0M | −$138,115 | −$10,113 |
| Net income | −$24.8M | −$21.1M | $2.4M | $380,811 | −$10,113 |
| Basic EPSper diluted share | -$0.34 | -$0.31 | $0.27 | $0.12 | -$0.01 |
| Diluted EPSper diluted share | -$0.34 | -$0.31 | $0.27 | $0.12 | — |